Good Pharma Scorecard
We rank bio-pharmaceutical companies and new drugs on ethics and public health performance criteria, focusing on issues that are critical to patients.
We rank bio-pharmaceutical companies and new drugs on ethics and public health performance criteria, focusing on issues that are critical to patients.
The Good Pharma Scorecard ranks companies and new medicines on their clinical trial transparency and data-sharing performance, taking into account ethics and legal standards. Subsequent versions of the scorecard will also evaluate the integrity of clinical trial designs, the accessibility of medicines, drug marketing practices, and other ethics and human rights issues.
Transparency is key to protecting and respecting research participants and users of medicines and vaccines
Evidenced based medicine requires all evidence to be in the public domain
Being able to learn from what other scientists have already done- both accomplishments and failures- stimulates innovation and ultimately the delivery of lifesaving results.
Transparency is key to maximizing the value of generated trial data and people’s participation in trials
Opacity can drive up costs of research and care
Transparency and data-sharing enable validation and replication of study findings
Roche / Genentech
Novartis
Merck
Bristol-Myers Squibb
Median: 92%
Gilead
Johnson & Johnson / Janssen
AstraZeneca
Valeant
Allergan
Company ranking
higher than last ranking
Company ranking
lower than last ranking
Company ranking
unchanged from last ranking